Medical device and MedTech insights, news, tips and more
MedRhythms Announces FDA Listing of InTandem™ (MR-001) to Improve Walking and Ambulation in Adults with Chronic Stroke
July 6, 2023
MedRhythms announced that MR-001, the company’s evidence-based neurorehabilitation system to improve walking and ambulation in adults with chronic stroke walking deficits, has been listed as a Class II medical device with the U.S. Food and Drug Administration (FDA). The system delivers an intervention based on the principle of Rhythmic Auditory Stimulation (RAS), a well-researched clinical intervention utilizing the mechanism of auditory-motor entrainment, through which the motor and auditory systems in the brain subconsciously synchronize to an external cue, such as music.
MedRhythms also unveiled the brand name for MR-001: InTandem™. The InTandem name reflects both the synchronization inherent in the device’s mechanism of action and the partnership formed between patient and device.
“Today is a historic day for MedRhythms and an essential accomplishment as we work to bring a new care solution to the 3.5 million people who struggle with mobility and independence long after the incidence of a stroke,” said Brian Harris, CEO and Co-Founder of MedRhythms. “During my time as a clinician at Spaulding Rehabilitation Hospital, I saw the positive impact that standardized interventions using music could have on the mobility of my patients. I am honored and proud that our team has committed to our mission of translating these interventions into evidence-based medical devices that can be utilized in home settings, breaking down several historic barriers to access. This important milestone enables the world’s first prescription music platform, and is a remarkable day for our company, for music, for healthcare, and most importantly for stroke survivors.”
Every 40 seconds, a person in the United States experiences a stroke, according to the Center for Disease Control (CDC), and the total financial impact of stroke in the United States exceeded $56 billion between 2018 and 2019. The burden on patient functioning is also profound. More than half of stroke survivors aged 65 and older experience reduced mobility, and stroke has become a leading cause of long-term disability.
InTandem, which is designed to be used independently by a patient in a home setting, received Breakthrough Device Designation from the FDA in 2020. Earlier this year, MedRhythms announced successful completion of a pivotal clinical trial for InTandem.
“The listing of InTandem demonstrates MedRhythms’ unwavering commitment to developing a safe, effective product that adheres to the stringent guidelines set forth by the FDA,” said Danielle Parker, Head of Regulatory and Quality at MedRhythms. “As we prepare for the next phase of InTandem’s product life cycle, we remain committed to meeting the needs of our patients while upholding the highest quality standards.”
InTandem is anticipated to be available soon in select market segments.
To learn more about InTandem visit: medrhythms.com/intandem
Media Inquiries: email@example.com
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company’s platform combines sensors, software, and music (via a partnership with Universal Music Group) with advanced neuroscience to target neural circuitry. The company is developing a pipeline of digital therapeutics across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson’s disease. The company’s product for chronic stroke walking deficits received Breakthrough Device Designation in 2020 and the company raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine. For more information, visit www.medrhythms.com.
See Full Press Release at the Source: MedRhythms Announces FDA Listing of InTandem™ (MR-001) to Improve Walking and Ambulation in Adults with Chronic Stroke
Press Release by: MedRhythms
Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.